ARCHIVES

Troubles of Two Landmark Cancer Drugs, Celebrex and Iressa, Likely to Shape cancer Prevention, FDA Policy. FDA Mulls Withdrawal of Iressa.

This article is from The Cancer Letter archive.

Vol. 31 No. 01 | January 7, 2005

Download PDF Visit The Full Archive

Related Articles

Steiner To Leave ICC, Says Someone Else May Do Better

December 10, 1982

Harkin, Specter Propose A $5.2-Billion Supplement For NIH. Senate Report Says NIH Funding At “Crisis Point.”

July 18, 2008

EntreMed Begins Phase I/II Trial For Endostatin.

July 27, 2001

St. John’s Wort Not Indicated For Patients On Irinotecan

May 31, 2002

In Brief: Einhorn Named Karnofsky Lecturer; Consensus Conferences On Colon, Breast Cancer Planned

February 2, 1990

NCI Director Klausner Resigns To Head Institute Begun By AOL Chairman Case.

September 14, 2001